End-of-day quote
Shenzhen S.E.
06:00:00 2024-07-10 pm EDT
|
5-day change
|
1st Jan Change
|
3.12
CNY
|
+3.31%
|
|
+2.30%
|
-26.07%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
3,795
|
4,989
|
5,592
|
5,675
|
5,013
|
4,989
|
Enterprise Value (EV)
1 |
3,895
|
4,809
|
5,900
|
7,098
|
6,462
|
6,321
|
P/E ratio
|
107
x
|
117
x
|
59.1
x
|
43.6
x
|
27.7
x
|
26.5
x
|
Yield
|
0.93%
|
0.24%
|
0.32%
|
0.38%
|
0.5%
|
0.5%
|
Capitalization / Revenue
|
2.74
x
|
3.41
x
|
3.46
x
|
3.64
x
|
3.1
x
|
3.05
x
|
EV / Revenue
|
2.81
x
|
3.29
x
|
3.65
x
|
4.55
x
|
3.99
x
|
3.86
x
|
EV / EBITDA
|
21
x
|
23.3
x
|
26.2
x
|
19.8
x
|
17.3
x
|
13.5
x
|
EV / FCF
|
28.4
x
|
15.3
x
|
-186
x
|
-11.2
x
|
48.8
x
|
21.6
x
|
FCF Yield
|
3.52%
|
6.53%
|
-0.54%
|
-8.93%
|
2.05%
|
4.64%
|
Price to Book
|
1.74
x
|
2.29
x
|
2.48
x
|
2.39
x
|
1.98
x
|
1.85
x
|
Nbr of stocks (in thousands)
|
1,182,213
|
1,182,213
|
1,182,213
|
1,182,213
|
1,182,213
|
1,182,213
|
Reference price
2 |
3.210
|
4.220
|
4.730
|
4.800
|
4.240
|
4.220
|
Announcement Date
|
4/19/19
|
3/30/20
|
3/19/21
|
3/30/22
|
3/24/23
|
4/24/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,384
|
1,462
|
1,616
|
1,561
|
1,619
|
1,636
|
EBITDA
1 |
185.4
|
206.8
|
225.2
|
358.1
|
373.8
|
468.6
|
EBIT
1 |
71.81
|
96.57
|
114.5
|
226.6
|
226.6
|
344.8
|
Operating Margin
|
5.19%
|
6.61%
|
7.08%
|
14.52%
|
13.99%
|
21.08%
|
Earnings before Tax (EBT)
1 |
43.56
|
67.41
|
111.6
|
150.3
|
205.9
|
230.5
|
Net income
1 |
38.79
|
42.07
|
94.62
|
130.4
|
180.8
|
188.1
|
Net margin
|
2.8%
|
2.88%
|
5.85%
|
8.35%
|
11.16%
|
11.49%
|
EPS
2 |
0.0300
|
0.0360
|
0.0800
|
0.1100
|
0.1530
|
0.1590
|
Free Cash Flow
1 |
137
|
314.3
|
-31.71
|
-634.2
|
132.5
|
293.2
|
FCF margin
|
9.9%
|
21.5%
|
-1.96%
|
-40.63%
|
8.18%
|
17.92%
|
FCF Conversion (EBITDA)
|
73.91%
|
151.95%
|
-
|
-
|
35.44%
|
62.57%
|
FCF Conversion (Net income)
|
353.11%
|
747.05%
|
-
|
-
|
73.26%
|
155.89%
|
Dividend per Share
2 |
0.0300
|
0.0100
|
0.0150
|
0.0180
|
0.0210
|
0.0210
|
Announcement Date
|
4/19/19
|
3/30/20
|
3/19/21
|
3/30/22
|
3/24/23
|
4/24/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
99.8
|
-
|
308
|
1,423
|
1,450
|
1,332
|
Net Cash position
1 |
-
|
180
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
0.5382
x
|
-
|
1.367
x
|
3.974
x
|
3.879
x
|
2.842
x
|
Free Cash Flow
1 |
137
|
314
|
-31.7
|
-634
|
132
|
293
|
ROE (net income / shareholders' equity)
|
1.97%
|
2.01%
|
4.23%
|
5.62%
|
7.19%
|
7.21%
|
ROA (Net income/ Total Assets)
|
1.49%
|
2.06%
|
2.34%
|
3.13%
|
2.62%
|
4.17%
|
Assets
1 |
2,609
|
2,042
|
4,051
|
4,169
|
6,898
|
4,506
|
Book Value Per Share
2 |
1.840
|
1.840
|
1.910
|
2.010
|
2.140
|
2.280
|
Cash Flow per Share
2 |
0.5200
|
0.3200
|
0.1900
|
0.3500
|
0.1900
|
0.2000
|
Capex
1 |
45.5
|
32
|
58
|
27.9
|
42.3
|
45.9
|
Capex / Sales
|
3.29%
|
2.19%
|
3.59%
|
1.78%
|
2.61%
|
2.8%
|
Announcement Date
|
4/19/19
|
3/30/20
|
3/19/21
|
3/30/22
|
3/24/23
|
4/24/24
|
|
1st Jan change
|
Capi.
|
---|
| -26.07% | 508M | | +25.76% | 45.45B | | +34.85% | 24.63B | | +30.64% | 16.9B | | +21.47% | 14.57B | | +70.35% | 14.02B | | -0.05% | 6.79B | | -10.06% | 6.61B | | +15.26% | 5.79B | | -8.87% | 5.73B |
Generic Pharmaceuticals
|